Wegovy and Heart Health: What the SELECT Trial Shows

What the SELECT Trial Actually Found (and Why It Matters)

When researchers launched the SELECT trial, they had a straightforward question: could semaglutide—the active ingredient in Wegovy—do more than help people lose weight? The answer, according to data published in the New England Journal of Medicine, appears to be yes. The trial enrolled approximately 17,500 adults with obesity or overweight, none of whom had diabetes, but all of whom had established cardiovascular disease. After a median follow-up period of roughly 3.3 years, participants taking semaglutide 2.4 mg weekly showed a significant reduction in major adverse cardiovascular events.

The primary endpoint combined three outcomes: heart attack, stroke, and cardiovascular death. The result was striking—a roughly 20% relative risk reduction in this composite endpoint compared to placebo. That number represents a meaningful difference in real terms, not just statistics. Researchers calculated a number needed to treat (NNT) that translated this relative figure into something patients could understand: for every certain number of people treated over the trial period, one fewer experienced a major cardiovascular event. This kind of concrete benchmark matters when you're discussing treatment decisions with your doctor, and it's the kind of practical detail you'll find explained further at OzemBlog.

Going into the trial, researchers hoped for positive results but weren't certain they'd see such a pronounced effect in a population without diabetes. The magnitude of benefit exceeded what many in the field had predicted, making the findings particularly noteworthy for preventive cardiology.

Heart Attack, Stroke, and Cardiovascular Death: Breaking Down Each Component

While the composite endpoint grabbed headlines, digging into the individual components reveals important nuance. The trial tracked heart attack, stroke, and cardiovascular death separately, allowing researchers to see where semaglutide's effects were strongest. Each component showed a reduction, though the degree of benefit varied between them.

One crucial finding involved timing. Statistical significance for the overall result emerged at approximately 6 months into the trial, but the benefits clearly accumulated over time rather than appearing immediately. This matters for patients wondering whether they should expect rapid results—cardiovascular protection from semaglutide appears to build gradually, consistent with the biological processes involved in atherosclerosis and vascular health.

Understanding the distinction between relative and absolute risk reduction helps frame expectations appropriately. The 20% figure describes relative risk reduction—how much the risk decreased compared to the placebo group. Absolute risk reduction, which shows the actual difference in event rates between groups, tends to be smaller but more clinically meaningful for individual decision-making. Both numbers matter, and responsible discussion of trial results presents both rather than relying on whichever looks most impressive.

How Semaglutide Appears to Protect the Heart (Beyond Weight Loss Alone)

Weight loss undoubtedly contributes to cardiovascular benefit—carrying less body weight generally means better blood pressure, improved lipid profiles, and reduced strain on the heart. However, researchers analyzing the SELECT data found evidence suggesting semaglutide offers cardiovascular protection through mechanisms beyond what weight loss alone would explain.

Several pathways appear relevant. Semaglutide reduces inflammation, as evidenced by decreases in C-reactive protein (CRP) levels observed among trial participants. The medication also appears to directly affect atherosclerosis progression, potentially stabilizing plaque and slowing the vascular damage that leads to heart attacks and strokes. Additionally, patients experienced improvements in blood pressure and cholesterol markers that exceeded what weight loss alone would predict.

Reduced insulin resistance and improved metabolic health seem to play a role as well. Even in people without diabetes, better metabolic function correlates with lower cardiovascular risk. Researchers believe these various mechanisms likely work together rather than one dominating—semaglutide seems to improve cardiovascular outcomes through a combination of effects on inflammation, metabolism, and traditional risk factors.

Who Saw the Biggest Benefit: Patient Characteristics in the Data

The SELECT trial included a diverse group of participants, allowing researchers to examine whether benefits varied by age, baseline BMI, or other characteristics. Participants ranged across age groups, and cardiovascular benefit appeared consistent across the spectrum rather than being limited to younger or older subgroups.

Baseline BMI around 33 kg/m² represented the average participant—clinically obese by standard measures. Benefit extended across different BMI levels within the study population, though those with higher baseline cardiovascular risk tended to show greater absolute benefit. A substantial proportion of participants were already taking statins at baseline, and semaglutide benefits appeared to add on top of the protection these medications provide rather than duplicating or replacing them.

The trial specifically enrolled people with established cardiovascular disease, meaning they already had documented heart or vascular disease before joining the study. This means the results apply most directly to similar patients—those who have already experienced cardiovascular events or have confirmed cardiovascular disease. Whether similar benefits would occur in lower-risk populations remains an open question that ongoing research aims to answer.

FDA Approval and What the Cardiovascular Indication Means in Practice

In March 2024, the FDA officially added cardiovascular risk reduction to Wegovy's approved indications—a milestone that legitimized what the SELECT data had suggested. This approval specifically covers adults with established cardiovascular disease who have obesity or overweight, regardless of diabetes status. It's important to distinguish this from Ozempic, which contains the same active ingredient (semaglutide) but is approved for diabetes management based on different study populations and dosing.

For physicians, this indication changes prescribing conversations. A patient who meets criteria for established cardiovascular disease can now be prescribed Wegovy with explicit cardiovascular protection as a goal—not just weight management. This matters because insurance coverage, patient motivation, and clinical prioritization can all shift when a medication has a recognized cardiovascular indication beyond its original purpose.

The practical difference matters: prescribing solely for weight loss involves different considerations than prescribing with a cardiovascular risk reduction indication, though both goals often coexist in the same patient. Understanding these nuances can help patients have more productive discussions with their healthcare providers, and resources like OzemBlog work to explain these distinctions in accessible language.

What This Means for Patients Considering or Already Using GLP-1 Therapy

If you have established cardiovascular disease and obesity or overweight, discussing semaglutide with your doctor may be worth considering. The SELECT data suggests meaningful cardiovascular protection in exactly this population. However, several caveats apply.

Do not stop other cardiovascular medications when starting semaglutide. Statins, blood pressure drugs, and other cardioprotective therapies should continue as prescribed. Semaglutide appears to add benefit on top of these treatments rather than replace them. For more details on how semaglutide fits into broader treatment strategies, OzemBlog offers articles breaking down the practical implications of these findings.

Set realistic timeline expectations. The trial showed benefits accumulating over approximately 3 years of follow-up. Cardiovascular protection isn't immediate, and treatment should be viewed as a long-term commitment. Gastrointestinal side effects, common with semaglutide, did not appear to offset cardiovascular benefits in the trial data—though managing these side effects remains important for treatment adherence.

Open questions remain. Longer-term follow-up beyond 3.3 years, benefits in lower-risk populations without established cardiovascular disease, and effects in specific subgroups still require additional research. The SELECT trial moved the field forward substantially, but science continues advancing.

The Bigger Picture: GLP-1 Drugs as Cardiovascular Medicine

SELECT isn't the only trial showing cardiovascular benefits for GLP-1 receptor agonists. A growing body of evidence from other medications in this class demonstrates similar patterns, suggesting the cardioprotective effects may be a class effect rather than unique to semaglutide. This evidence base is reshaping how cardiologists think about these medications.

Preventive cardiology guidelines are evolving accordingly. Cardiologists who previously rarely prescribed these medications now face mounting evidence supporting their use in appropriate patients. Healthcare systems are adapting to incorporate GLP-1 therapy into cardiovascular risk reduction strategies, a shift that would have seemed unlikely just a few years ago.

Ongoing studies continue expanding the evidence base into different populations, including those with heart failure, chronic kidney disease, and other conditions. This moment represents a genuine evolution in cardiometabolic medicine—where medications initially approved for diabetes and obesity are becoming tools for preventing heart attacks and strokes in broader populations. The story isn't finished, but the chapter opened by the SELECT trial marks a meaningful turning point in how we approach cardiovascular prevention.

FAQ

How much did semaglutide reduce heart attack and stroke risk in the SELECT trial?

The trial found approximately a 20% relative risk reduction in the combined endpoint of heart attack, stroke, and cardiovascular death among participants taking semaglutide 2.4 mg weekly compared to placebo over roughly 3.3 years of follow-up.

Do I need to have diabetes to get cardiovascular benefits from Wegovy?

No. The SELECT trial specifically studied people with obesity or overweight who did not have diabetes but did have established cardiovascular disease. This evidence base supports cardiovascular benefits in this specific population.

How long does it take to see heart benefits after starting Wegovy?

Statistical significance was reached at approximately 6 months into the trial, but benefits accumulated over the full follow-up period of roughly 3.3 years. Cardiovascular protection from semaglutide appears to develop gradually rather than immediately.

Can I stop my statin if I start taking Wegovy?

No. The SELECT trial found that semaglutide benefits added on top of standard cardioprotective medications including statins. Do not stop any cardiovascular medications without discussing with your doctor first.

Is the cardiovascular benefit just from weight loss?

Evidence suggests weight loss contributes but doesn't fully explain the cardiovascular protection observed. Researchers identified additional mechanisms including anti-inflammatory effects, direct action on atherosclerosis, and improvements in metabolic health that appear to work alongside weight loss.

Sources

• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
• Novo Nordisk announces FDA approval of Wegovy for cardiovascular risk reduction